7:53 am AbbVie beats by $0.09, beats on revs; raises FY15 EPS, ~in-line (ABBV) : Reports Q1 (Mar) earnings of $0.94 per share, excluding non-recurring items, $0.09 better than the Capital IQ Consensus Estimate of $0.85; revenues rose 10.5% year/year to $5.04 bln vs the $4.97 bln consensus.
On an operational basis, sales increased 17.8 percent, excluding a 7.3 percent unfavorable impact from foreign exchange rate fluctuations.
First-quarter sales growth was driven by the continued strength of HUMIRA and other promoted products. Global HUMIRA sales increased 18.0 percent, or 26.0 percent on an operational basis, excluding the impact of foreign exchange rate fluctuations.
Total company sales growth was also driven by the launch of Viekira, as well as strong operational growth from other key products including Synagis, Synthroid, Creon and Duodopa. Viekira sales $231 mln
Co raises FY15 adj. EPS to $4.10-4.30 from $4.05-4.25 vs. $4.29 Consensus.